Your browser doesn't support javascript.
loading
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy, Joyce; Brufsky, Adam; Rugo, Hope S; Tolaney, Sara M; Punie, Kevin; Sardesai, Sagar; Hamilton, Erika; Loirat, Delphine; Traina, Tiffany; Leon-Ferre, Roberto; Hurvitz, Sara A; Kalinsky, Kevin; Bardia, Aditya; Henry, Stephanie; Mayer, Ingrid; Zhu, Yanni; Phan, See; Cortés, Javier.
Afiliação
  • O'Shaughnessy J; Medical Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, 3410 Worth St., Suite 400, Dallas, TX, 75246, USA. joyce.oshaughnessy@usoncology.com.
  • Brufsky A; Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Rugo HS; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Sardesai S; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
  • Loirat D; Medical Oncology Department and D3i, Institut Curie, Paris, France.
  • Traina T; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Leon-Ferre R; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Hurvitz SA; Medical Oncology, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Kalinsky K; Columbia University Irving Medical Center, New York, NY, USA.
  • Bardia A; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Henry S; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.
  • Mayer I; Department of Oncology-Hematology, Radiotherapy, and Nuclear Medicine, CHU UCL Namur, Namur, Belgium.
  • Zhu Y; Breast Cancer Program, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Phan S; Department of Biostatistics, Gilead Sciences, Inc., Foster City, CA, USA.
  • Cortés J; Department of Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.
Breast Cancer Res Treat ; 195(2): 127-139, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35545724
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama / Imunoconjugados / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama / Imunoconjugados / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos